Proterguride

Proterguride
Clinical data
Other namesVUFB-13416; VUFB13416; ZK-39437; ZK39437; 6-Propylterguride; 6-Propyl-9,10-dihydrolisuride; N,N-Diethyl-N'-(6-propylergolin-8α-yl)urea
Drug classDopamine agonist; Prolactin inhibitor; Antiparkinsonian agent
ATC code
  • None
Identifiers
  • 3-[(6aR,9S,10aR)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H32N4O
Molar mass368.525 g·mol−1
3D model (JSmol)
  • CCCN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)NC(=O)N(CC)CC
  • InChI=1S/C22H32N4O/c1-4-10-26-14-16(24-22(27)25(5-2)6-3)12-18-17-8-7-9-19-21(17)15(13-23-19)11-20(18)26/h7-9,13,16,18,20,23H,4-6,10-12,14H2,1-3H3,(H,24,27)/t16-,18+,20+/m0/s1
  • Key:FCRJELOYDVBTGW-ILZDJORESA-N

Proterguride (INNTooltip International Nonproprietary Name; developmental code names VUFB-13416, ZK-39437), also known as 6-propylterguride or 6-propyl-9,10-dihydrolisuride, is a dopamine agonist of the ergoline family described as a prolactin inhibitor and antiparkinsonian agent which was never marketed. It is closely structurally related to certain other ergolines like terguride and lisuride. Besides dopamine receptors, the drug also interacts with serotonin, adrenergic, and histamine receptors. Proterguride was first described in the literature by at least 1981.

See also